Targeting aging with Rapamycin: On the path toward 21st Century Medicine

A good update on the most current science related to rapamycin in longevity, by Matt Kaeberlein, from a conference this past summer.

I highly recommend anyone interested, or using, rapamycin to listen to this video. He touches upon rapamycin/mtor and ovarian aging, immune system / Covid and Influenza and rapamycin, and much more. In other presentations Matt has said that the results from the Dog Aging Project / TRIAD program (using rapamycin) are anticipated in 2026. The 2021 paper by Mannick et al, on the phase 2 and 3 clinical study mentioned by Matt in the video is here: Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials - The Lancet Healthy Longevity

Related:

9 Likes

Excellent overview! I can not get enough Kaeberlein on his research and perspective. He believes rapamycin does slow, reverse aging and extends life span with health. His taking rapamycin shows that confidence.

3 Likes

Well, as long as you can’t get enough of Kaeberlein… I’ve discovered that Optispan, the new investment fund that Matt is involved with has created a YouTube channel and posted a few videos (and has all of 11 subscribers so far :-). Here are two other videos of Matt’s that they’ve posted:

An Introduction to the Biology of Aging:

Seems the video above may be a bit outdated. The oldest mole rat in captivity turned 39 this year, and he’s still young(ish) and healthy. He’s still breeding. We really don’t know how long they can live to, but I would say 40-50 is more like it. Actually, I hope these little guys can pull an energizer bunny and keep going and going and going…

Although they’ll never be as cute.

2 Likes

Matt Kaeberlein rocks.

2 Likes

Matt and Attia are by far the best communicators and advocates of aging research. Green and Blagosklonny have added a lot to the field, but neither one can communicate well.

5 Likes

Dr. B has written some very convincing papers. He is just better at writing.

2 Likes

Question: I think I read on this site that Blagosklonny wants to educate medical profession, but does NOT want individuals to self-medicate. If true, his info may be useful, but he is not a friend, especially since these days, members of this site, tend to know far more than MDs, & take Rapa, generally on their own.

2 Likes

I think he wants rapamycin / longevity medicine to go mainstream and the degree to which people avoid doctors and just take the biohacker / self medication approach it doesn’t move the medical field forward towards more of a “healthcare rather than sickcare” model that many of us thing is the better approach…

A new interview (written) with Matt Kaeberlein:

There are a few interesting questions. One, if you had tested a million compounds, would you find something better than rapamycin? I would be shocked if you wouldn’t, but that’s an unknown at this point. Another question is, “What happens when we start combining more than one thing that affects lifespan?”

There’s reason to believe that at least in some cases, combining two or three things could be beneficial, and we wanted to be able to explore that. This is where we decided to start with WormBot, because we felt like we had enough capacity to test individual drugs, and, in select cases, combinations.

The strategy we settled on was to start from FDA-approved drugs because not only are they approved for human use, but, usually, something is known about their mechanisms of action. They are also usually quite potent, so the chance to get a sizeable effect is higher.

2 Likes

Excellent updates… csn tease out some new information or at least some confirmation of best guesses and rapamycin. Thanks for this

I love the WormBot idea! That is something that could really improve the discovery of new drugs and combinations to improve longevity. It’s like shining the few first rays of light into a darkened room. Maybe we’ll be able to see the black cat after all…

2 Likes

More on the Wormbot business:

So to find out how robotics, AI, and worms could be combined to target aging and drug discovery, we reached out to Ora Biomedical’s co-founder and CEO, Mitchell Lee, to find out what the company has been up to since launching earlier this year.

1 Like

Another new interview, where Matt discusses his transition out of academia and over to Optispan Ventures…

1 Like